Key Takeaways
- Shares of Moderna plummeted 10.7% on July 10, 2026, shedding $8.17 to settle at $68.39
- Company insiders offloaded $6.2 million in stock over the past quarter with no purchases recorded
- First quarter earnings revealed a loss of $3.40 per share, falling short of the -$3.02 projection, while revenue of $389M surpassed the $236.37M estimate
- Analyst consensus leans toward “Reduce” with an average price target of $38.27
- QRG Capital Management initiated a fresh stake, acquiring 13,666 shares valued at approximately $694,000
The biotechnology company experienced a significant downturn on July 10, 2026, as shares plummeted 10.7%—losing $8.17 in value—to finish trading at $68.39. This decline continues a troubling trend for the vaccine manufacturer.
Trading commenced that session at $76.56. The company’s shares have fluctuated between $22.28 and $85.60 over the past year, positioning the current valuation in the upper portion of this range—though the recent downturn signals potential vulnerability at these levels.
The company’s latest quarterly results, unveiled on May 1, provided little comfort to shareholders. Moderna reported a per-share loss of $3.40, exceeding the anticipated deficit of -$3.02. Such disappointing figures typically leave lasting impressions on market participants.
On the revenue front, however, the picture looked brighter. The firm generated $389 million during the quarter, significantly outperforming the Wall Street consensus of $236.37 million. This represents a year-over-year surge of 260.2%.
Yet strong top-line growth can only offset so much when bottom-line performance remains deeply negative. The company continues to struggle with a net margin of -143.55% and a return on equity of -26.64%.
Corporate Insiders Reduce Their Stakes
Executives and board members have been offloading shares at a notable pace. Throughout the previous 90 days, insiders disposed of $6.2 million in company stock—with zero acquisitions recorded during that timeframe.
Board member Noubar Afeyan divested 9,263 shares on May 21 at $46.84 apiece, trimming his holdings by 70.24%. Company President Stephen Hoge unloaded 53,336 shares on June 15 at $51.37 per share, generating proceeds of approximately $2.74 million.
While these transactions occurred under predetermined 10b5-1 trading arrangements, the consistent pattern of selling rarely escapes investor scrutiny.
Company insiders maintain ownership of 10.80% of outstanding shares. Institutional investors control 75.33%.
Analyst Community Remains Skeptical
The Wall Street research community hasn’t embraced Moderna with enthusiasm. Among 18 analysts tracking the stock, just two recommend buying, eleven advocate holding, and five suggest selling. This consensus translates to a “Reduce” recommendation.
The collective price target stands at $38.27—substantially below current trading levels.
Morgan Stanley recently adjusted its target from $33 to $39 while maintaining an “equal weight” stance. Goldman Sachs lifted its objective from $43 to $49 with a “neutral” designation. Bank of America raised its target from $34 to $38 but retained an “underperform” rating.
Weiss Ratings affirmed a “sell (d-)” recommendation on June 12.
Among institutional investors, QRG Capital Management established a new holding during the first quarter, purchasing 13,666 shares valued at roughly $694,000. Several other smaller investment firms also initiated positions, though the amounts remained relatively minor.
Moderna’s GF Score registers at 58 out of 100. The company scores 7/10 for Financial Strength and 7/10 for Growth, but achieves only 3/10 in Profitability.
The stock’s 50-day moving average sits at $55.75. The 200-day moving average stands at $49.53. Wall Street analysts collectively project full-year earnings per share of -$6.51.
